SCHEDULE 13G: Alyeska Investment Group Discloses 9.9% Passive Stake in IN8BIO, Inc.

Alyeska Investment Group, L.P. and its affiliates have reported a 9.9% beneficial ownership stake in IN8BIO, Inc. as of December 31, 2024, held for ordinary course of business.

Summary

• Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh collectively reported beneficial ownership of 7,241,076 shares of IN8BIO, Inc. common stock.
• This ownership represents 9.9% of the total outstanding common stock of IN8BIO, Inc.
• The reported stake comprises 5,063,291 shares of Class A common stock directly held and an additional 2,177,785 shares exercisable from warrants, limited by a 9.99% exercise cap.
• The percentage calculation is based on 72,483,253 outstanding shares of IN8BIO, Inc. Common Stock, as reported in the Issuer's Form 10-Q filed on November 12, 2024.
• The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of IN8BIO, Inc.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The document is a routine regulatory filing for a passive investment. The presence of a significant stake by a reputable investment group could be viewed as a positive signal of confidence in the company, without implying any active management involvement or immediate strategic changes.

Positives

• The disclosure of a significant 9.9% stake by Alyeska Investment Group, a notable investment firm, could be interpreted by the market as a vote of confidence in IN8BIO, Inc.'s long-term prospects.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding IN8BIO, Inc.'s future outlook.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification from Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh)

Industry Context

This filing represents a significant passive investment by a major institutional investor in a biotechnology company. Such disclosures are common and reflect an investor's position in a company, often signaling confidence in the company's long-term potential within the healthcare and biopharmaceutical sectors.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure required when an institutional investor acquires beneficial ownership of more than 5% of a company's stock with a passive investment intent. There are no specific financial results or operational metrics within this document to compare against industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: May perceive the significant investment by Alyeska Investment Group as a positive indicator, potentially bolstering investor confidence in IN8BIO, Inc.
• Company Management: Will be aware of a large, passive institutional investor on their shareholder register, which is a common occurrence for publicly traded companies.

Next Steps

• The reporting persons will be required to file amendments to this Schedule 13G if there are significant changes to their beneficial ownership percentage or investment intent.

Key Dates

Recommendation

Keywords

IN8BIO, Alyeska Investment Group, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Biotechnology, SEC Filing